• Most significant patent filed is also the most comprehensive, covering broad areas of cannabinoid polymeric nanoparticles and fibers
• Company is committed to continuing research program and expand its intellectual property portfolio over the coming months
• MCTC participating in multiple growing verticals within global cannabis industry through acquisitions, strategic partnerships, and intellectual property

MCTC Holdings Inc. (OTC: MCTC), a cannabinoid science innovator focused on high-growth and high-margins sub-sectors of the cannabis and hemp industry, filed its fourth cannabinoid delivery technology patent. The patent broadly covers many aspects of nanoparticles and nano fibers comprising one or more cannabinoids disposed at least partially within a water-soluble medium, the company announced in a press release (http://ibn.fm/bCTyI).

MCTC’s R&D program continues with research into development of improved methods to give living systems access to cannabinoids. A key component of the research program is the development of novel polymeric nanofibers and nanoparticles, which have very high potential to significantly improve bioavailability, while allowing for tunability of cannabinoid combinations, ultra-high loading rates, precise dosing, and controlled release parameters at the same time.

According to CEO Arman Tabatabaei, this is the most significant patent the company has filed. “It is by far the most comprehensive covering broad areas of cannabinoid polymeric nanoparticles and fibers. The claims not only cover a plurality of particles within at least a partially water-soluble carrier, but also the process utilizing the precursor mixtures. Not only are nanoparticles and nanofibers included, but also particles below 1.5 microns,” Tabatabaei explained.

The company filed three other patents related to cannabinoid delivery systems in recent months. The first patent, which was on an edible dissolvable film for the delivery of cannabinoids, was the product of collaboration between MCTC and Cannabis Nanosciences, Inc. The companies also cooperated on the second patent, filed on cannabinoid nanoparticles combining TPGS, a water-soluble form of vitamin E. TPGS is a proven and safe bioenhancer of cannabinoids and other hydrophobic compounds. MCTC’s third patent was for a unique 3D printed, 4-dimensional, shape-changing cannabinoid delivery system for beverages.

“We expect to continue to expand our intellectual property portfolio over the coming weeks and months as our research and development programs continue. We believe the area of cannabinoid delivery systems is one of the most exciting areas of the growing cannabinoid sciences arena,” Tabatabaei added.

Currently pending a name change to Cannabis Global, Inc., MCTC Holdings is an integrated cannabis business operation focused on multiple verticals within the fast-growing cannabis and hemp industries via acquisitions, partnerships and intellectual property. An innovator in the field of cannabinoid nanoparticles and infusion technologies, the company concentrates its efforts on the middle part of the industry’s value chain, characterized by high margins and high growth. Its advanced cannabinoid delivery system research can revolutionize the science of cannabinoid bio-enhancement for use in foods, beverages, consumer products and transdermal applications, with the potential for exponential growth in the industry.

For more information, visit the company’s website at www.CannabisGlobalInc.com

NOTE TO INVESTORS: The latest news and updates relating to MCTC are available in the company’s newsroom at http://ibn.fm/MCTC

• Studies have shown a greater than 2.2-fold reduction in narcotic use over the first 48 hours post-op
• SofPulse (R) use causes 500% increase in new blood vessels, 59% increase in surgical wound recovery, 57% reduction in pain at one-hour post-op, 55% less pain medication and 50% less inflammation
• Bioelectric medicine is a $17 billion market, projected to exceed $33 billion annually by 2025

Commercial-stage developer of innovative medical devices Endonovo Therapeutics Inc.’s (OTCQB: ENDV) proprietary SofPulse(R) technology is being successfully used by surgeons at New Hanover Regional Medical Center (NHRMC) in North Carolina to reduce the volume of opioid prescriptions and remove the need for patients to take narcotics for pain after surgery.

According to a WECT.com report, NHRMC has been using SofPulse(R) for six months, during which medical staff noticed a 30-40 percent drop in post-op narcotic prescriptions (http://ibn.fm/KQSDf). The report quoted urologist Dr. Roc McCarthy as detailing several benefits of the technology, including faster recovery times and fewer people asking for pain medication.

The non-invasive SofPulse(R) device uses electromagnetic waves to reduce inflammation after surgery. It is the flagship product of Endonovo Therapeutics and its proprietary Electroceutical(R) Therapy, developed for the treatment of inflammation, cardiovascular disease, and central nervous system disorders such as traumatic brain injury (TBI), acute concussions, post-concussion syndrome, and multiple sclerosis.

According to McCarthy, many patients are receptive to the SofPulse(R) device and opt to use it instead of pain medication because they are worried about the side effects of opioids, including addiction risks in the context of the national opioid crisis. The opioid crisis has reached a peak in the country, putting intense pressure on pharmaceutical companies, health care providers, and medical facilities to reduce the use of painkillers. This has created demand for other viable pain control solutions, which were quite limited until recently.

While the technology behind SofPulse(R) isn’t new, it has not been fully developed until now, McCarthy added. “It’s just opening the door to a world of opportunity for people to come up and innovate other ways of decreasing the amount of pain that people are having,” he said.

SofPulse(R) has prospects to reduce the need and intake of prescription drugs over the long term. Studies have shown a greater than 2.2-fold reduction in narcotic use over the first 48 hours post-procedure. This is a positive development in light of 2010 data of the Department of Health and Human Services, according to which 31% of adverse events and 42% of temporary harm events among Medicare patients in acute care hospitals were related to medication.

According to Endonovo data, the technology leads to a 500% increase in new blood vessels, 59% increase in surgical wound recovery, 57% reduction in pain at one-hour post-op, 55% less pain medication, and 50% less inflammation. SofPulse(R) works by restoring key electrochemical processes that initiate anti-inflammatory and growth-factor cascades necessary for recovery to occur (http://ibn.fm/JkQNY).

Endonovo’s Electroceutical(R) Therapy is certified for the treatment of chronic wounds by the Centers for Medicare and Medicaid Services (CMS) nationwide. The success of this proprietary device is rapidly broadening the company’s horizons, providing them with new and unique opportunities to enter the buoyant bioelectric medicine market, which is currently worth $17 billion and projected to exceed $33.14 billion annually by 2025 (http://ibn.fm/AZEdK).

Endonovo developed its SofPulse(R) technology in collaboration with researchers and medical centers. The wearable, non-invasive pain reducer continues to undergo testing as a way of limiting opioid use with emphasis on post-surgical pain relief and recovery. These technological developments represent massive, long-term valuation potential for the company.

For more information, visit the company’s website at www.Endonovo.com

NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at http://ibn.fm/ENDV

• Former Head of Digital Commerce at HSN, Jill Braff brings a wealth of experience in marketing, e-commerce to her new role
• CEO believes PLUS online CBD business will be transformative for the company
• Braff deems PLUS one of most promising companies in a high-growth industry

Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF), a leading cannabis-branded product company with the two best-selling cannabis products in California, recently announced the appointment of ecommerce senior executive Jill Braff to the company’s board of directors (http://ibn.fm/8hJSE). The move is aimed at further strengthening the company’s already impressive digital sales and marketing expertise.

“We couldn’t be more thrilled that Jill has agreed to join the PLUS family as the fifth member of our board of directors,” PLUS co-founder and CEO Jake Heimark stated in a news release. “Her experience in both digital and traditional marketing makes her the perfect fit as we continue to grow our online CBD business, a distribution channel that we believe will be transformative for the PLUS brand. I look forward to leaning on her insight and invaluable experience as we navigate the rapidly evolving world of direct-to-consumer sales and marketing.”

Currently serving as president of Brit + Co, Braff brings a wealth of experience in marketing and e-commerce to this new responsibility. Braff has shouldered senior executive roles at a number of well-known companies including HSN, where she was executive vice president over digital commerce; Ellen (DeGeneres) Digital Ventures, where she was general manager; and Ancestry.com, where she was vice president of marketing.

“The opportunity to join PLUS, one of the most promising companies in a high-growth industry like cannabis, is extremely exciting,” Braff added. “I’m a fan of early market leaders. The deliberate and focused approach PLUS has taken to building a branded-products company drew me to this opportunity, and I look forward to playing a key role in advancing the company’s strategy forward.”

In her previous roles, Braff received numerous honors and awards, including being recognized as one of the Top Women in Digital by Cynopsis Media and one of the 40 Most Influential People under 40 by Silicon Valley Business Journal.

Braff joins PLUS at a pivotal point in time. The Plus Products’ cannabis-infused edibles are now available in more than 360 licensed retailers across the state of California, and the company recently launched its products in Nevada, one of the nation’s most promising cannabis markets. In addition, PLUS has unveiled a line of 100% hemp-CBD-infused gummies, available on its website (http://ibn.fm/Zs0Xi). The company’s mission is to make cannabis safe and approachable, which begins with high-quality products that deliver consistent consumer experiences.

For more information, visit the company’s website at www.PlusProducts.com

NOTE TO INVESTORS: The latest news and updates relating to PLPRF are available in the company’s newsroom at http://ibn.fm/PLPRF

• Predictive Oncology subsidiary TumorGenesis developing new PDx models needed to understand the complexities of cancer
• Tremendous unmet need for patient-derived tumors (PDx) for new drug development – current mouse models unreliable
• TumorGenesis unique in the industry; its ovarian-cancer cells haven’t been widely available like most other PDx samples
• Multi-billion-dollar market opportunity

As the precision-medicine industry continues to integrate technology to improve the efficiency and efficacy of its strategies, clinicians are realizing the need for actual patient samples to determine the best methods to defeat cancer. Researchers are now turning to patient-derived tumors (PDx) to better understand the complexities and vagaries of the disease which has become the new focus in cancer research. Predictive Oncology Inc. (NASDAQ: POAI) is executing on its mission to deliver cutting-edge services for the oncology research and profiling market. The company’s subsidiary, TumorGenesis, was formed in 2018 with a mission to create reliable, reproducible and translatable cancer cell capture, culture and screening using lab-ready to use technologies.

TumorGenesis will build kits used in cancer research laboratories around the world. Kits, media and cells are valued today at $2.8 billion growing at CAGR 12.9% to $6.8 billion by 2025.Predictive Oncology believes TumorGenesis’ novel PDx platform will provide pharmaceutical and biotech companies the tools needed to identify, understand and attack tumors. Through the work of TumorGenesis on PDx profiles, Predictive Oncology intends to become an important conduit for rapid drug identification, development and approvals – objectives worth billions in the space.

PDx models have proved to be a critical component of early cancer detection and the global research community has focused efforts on mastering the complexities of cancer and moving rapidly to PDx models to do so. There’s now a major emphasis in cancer research to learn more about cancer’s origins and find ways to identify early that cancer is present and then prevent or treat cancer cells and cancer cell colonies in their infancy, long before overt symptoms of cancer reveal themselves. Certain cancers like ovarian, pancreatic and brain cancers as well as many others, are highly metastatic, have little if any treatment options and little reliable way of early detection.

However, to study cancer cells, they must be isolated and perpetuated: in short, immortalized. Unfortunately, this process created more aberrations of the genetics of the isolated cancer cells. The isolation or “immortalization” of these cancer cell lines also created what researchers call homogeneous cancer colonies, meaning the cancer cells all behaved the same way.

Tumors are not homogeneous but are heterogeneous and other researchers have found that the homogeneous cell lines are also admixed with clonal variants that can rapidly mutate even further, confounding research. Tumors and cancer cells are much more complex than originally perceived.

Everyone in the cancer research community has now focused efforts on mastering the culturing of cancer cells and preserving their in vivo (in patient) characteristics. The goal is to successfully grow in the laboratory and subsequently implanted in mice or rats (PDx Mouse and PDx Rat), a tumor that accurately represents the patient’s tumor. TumorGenesis is rapidly developing its technology in this multibillion-dollar industry of Patient Derived Tumors (PDx), the focus of all pharmaceutical, biotech, government and independent research institutes around the world.

TumorGenesis currently has 25 ovarian-cancer cell types that have been validated utilizing PDx samples. The company’s program includes plans to isolate these ovarian-cancer cell types and study their response to drugs, which is unique in the industry as these ovarian-cancer cells haven’t been widely available like almost all other PDx samples. This gives POAI, via TumorGenesis, a striking competitive advantage which can be measured both qualitatively and quantitatively. Using its unique PDx samples then screening drugs and drug combinations against its extensive library of ovarian-cancer cell types, TumorGenesis is building the kits that are desperately needed facilitate the development of new, more effective drugs that are created in response real human cancer cells. Through its utilization of PDx models, TumorGenesis’ work has synergistically supported Predictive Oncology’s quest to deliver the necessary tools to defeat ovarian cancer first then move to all other cancer sub-types. This is Predictive Oncology’s overarching strategy, delineated in its CancerQuest2020 initiative.

Predictive Oncology is a data and AI-driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for patients. POAI is at the vanguard of the latest scientific endeavors in cancer research: to better understand the complexities of individual cancers and tailor individualized therapeutic protocols. In addition to providing the molecular information necessary to help deliver on the promise of personalized medicine, the comprehensive molecular information delivered by Predictive Oncology is of enormous value to Pharma in new drug development and the PDx models developed by TumorGenesis may provide the pathways for Pharma to find successful solutions to the scourge of cancer.

For more information, visit the company’s website at www.Predictive-Oncology.com

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• Wholly owned subsidiary Mariner IC Inc. completes another successful licensing campaign around its Anchor Structure Portfolio
• Patent Licensing Revenues for the nine-months ended September 30, 2019 were approximately $2 million
• The company remains active in monetizing its existing portfolio as well as evaluating potential acquisitions
• QPRC trades on the OTCQB, offering investors an exciting opportunity to participate in the IP monetization space

The Anchor Structure Portfolio, acquired by company Quest Patent Research Corp. (OTCQB: QPRC) from Intellectual Ventures in October 2015 and transferred to wholly owned subsidiary, Mariner IC Inc., consists of two United States patents which relate to technology for incorporating metal structures in the corners and edges of semiconductor dies to prevent cracking from stresses.

Following the execution of funding agreements and the engagement of counsel, in 2016, Mariner IC brought patent infringement suits in the United States District Court for the Eastern District of Texas against MediaTek Inc., Texas Instruments Incorporated, LG Electronics Inc., Toshiba Corporation. Those cases were resolved in 2017, generating licensing fees of approximately $1.2 million.

In 2018, Mariner IC brought patent infringement suits in the United States District Court for the Eastern District of Texas against Sharp Corporation, AsusTek Computer Inc., TiVo Corporation and Huawei Device Co., Ltd et. al. As of September 30, 2019, the action against Huawei is currently stayed pending settlement and the actions against TiVo, AsusTek and Sharp were dismissed. Revenues for the period ended September 30, 2019, which were approximately $2 million according to the Company’s most recent quarterly report (http://ibn.fm/3gvxA), includes the revenue from these cases.

“IP monetization poses significant risks. Not only do you have to prove infringement, but a defendant can raise up to 27 patent defenses, any one of which can be case dispositive if successful. Our assets have to survive quite a gauntlet. The success of the Mariner campaigns certainly demonstrates management’s ability to identify, acquire and monetize valuable intellectual property,” Quest CEO Jon Scahill stated in a news release. “IP monetization is complex, costly and takes time to realize. We constantly evaluate ways to mitigate risk, reduce cost and accelerate the timing of our licensing efforts. Management has a clear vision for building long-term value centered around monetizing our existing portfolio as well as continuing to expand our portfolio of valuable IP. The objective is to replicate, many times over, the success shown by the Mariner campaigns.”

The Company has been extremely active in harvesting its existing portfolio of IP assets. Through the end of the third quarter, Quest has partially or fully resolved 8 cases with an additional 7 cases successfully stayed pending settlement.

Quest announced its listing on the OTCQB index in May as part of its growth efforts and plans to continually build financing and revenue sources (http://ibn.fm/ItqLX). The company’s annual revenues have grown from around $200,000 in 2015 to $7 million in patent licensing fees last year.

For more information, visit the company’s website at www.QPRC.com

NOTE TO INVESTORS: The latest news and updates relating to QPRC are available in the company’s newsroom at http://ibn.fm/QPRC

• ENDV has developed a viable pain-control solution for those seeking alternatives to highly addictive opioids
• The company’s flagship product is an FDA-cleared, easy-to-place, noninvasive device that delivers pulsed electromagnetic frequencies to targeted area
• In one study, patients treated with Endonovo technology reported a decrease in pain medication by nearly threefold

Amid mounting concern about the alarming opioid-addiction crisis, Endonovo Therapeutics Inc. (OTCQB: ENDV) offers one of the few bright spots on the horizon. Endonovo is the commercial-stage developer of noninvasive Electroceutical(TM) Therapeutic devices designed to target patient pain and inflammation, a viable pain-control solution for those desperately seeking options other than highly addictive drugs.

The crisis is real. The National Institute on Drug Abuse reports that 21% to 29% of patients prescribed opioids for chronic pain misuse them, and more than 130 people in the United States die every day after overdosing on opioids (http://ibn.fm/92SUO). The economic burden of the crisis is also heavy, with prescription opioid misuse alone in the United States totaling $78.5 billion annually including the costs of health care, lost productivity, addiction treatment and criminal justice involvement.

Endonovo provides an alternative. The company’s flagship product, SofPulse(R) Electroceutical(TM) Therapy is an FDA-cleared, easy-to-place, noninvasive device that delivers targeted pulsed electromagnetic field (tPEMF) frequencies to enhance postsurgical recovery. Used as a standalone therapy or integrated into any treatment protocol, SofPulse transmits gentle pulses to the tissue causing a positive biological effect to help reduce swelling and accelerate the body’s natural recovery process. Patients using SofPulse require significantly fewer prescription medications, potentially decreasing the adverse side effects of opioid medication.

Endonovo’s tPEMF technology is FDA approved for the treatment of post-operative pain and edema, with studies indicating that the technology is at least as effective as NSAIDs in the treatment of pain and swelling. In one study, patients treated with Endonovo tPEMF technology experienced a decrease in pain medication by nearly threefold compared to those who didn’t receive the therapy (http://ibn.fm/jkeC1).

Battery-operated and disposable, SofPulse(R) is a wearable device that delivers electromagnetic pulses either manually or in a preprogrammed mode that automatically provides 15 minutes of therapy every two hours. The pulses go through dressings, casts and clothing, and the convenient device allows a person to remain mobile while still receiving powerful treatment. The treatment can also be integrated into a variety of pain-management, wound-care and post-op protocols.

Endonovo is focused on providing clinical solutions substantiated with research and evidence-based data. The company also strives to be an educational resource for clinicians and has created a research library comprised of the latest clinical data, abstracts and media that focuses on tPEMF technologies. Based on the company’s key technological developments and innovative therapies, Endonovo may represent a significant long-term valuation potential.

For more information, visit the company’s website at www.Endonovo.com

NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at http://ibn.fm/ENDV

• Strategically deployed its premier, nationally recognized brands through wholesale, distribution, e-commerce, popup stores, affiliate and direct-to-consumer sales models, including Amazon FBA and Prime.
• Recognizes a massive opportunity to achieve significant market share in the booming billion-dollar CBD industry by utilizing NBDR’s technological, marketing and operations expertise to support its “best in class” line of CBD wellness and beauty products.
• Is the first and currently only company operating in the CBD space to offer its customers the peace of mind and security of having its third-party lab test results recorded and verified permanently and immutably on blockchain technology.
• Online sales of dental equipment and medical supplies, totaling $40 billion in 2018, are growing at an average annual rate of 17% compared with a 2% revenue growth rate at brick-and-mortar shops, according to research firm IBISWorld.
• IP portfolio includes five approved and several pending trademarks, in addition to several blockchain technology patents actively being filed and secured with the USPTO.
• Utilizes cutting-edge technologies to reduce costs while increasing revenues and shareholder value in existing product offerings as well as developing and deploying proprietary technology solutions, SAAS offerings and apps in several high-demand, lucrative markets.
• Active and transparent management team backed by highly specialized advisory board.
• Committed to operating as an industry leader in communicative and transparent public company operations while maintaining compliance and filings required by our regulators.
• Utilizing the structure and fundraising tools to build capital position while utilizing the capital and equity to acquire and scale brands, technology and revenues.

No Borders Inc. (OTC: NBDR) specializes in the acquisition, creation and scaling of commercial products by utilizing cutting-edge technologies designed to reduce costs while increasing revenues and shareholder value. With active subsidiaries in healthcare, education, cannabidiol (CBD), finance and technology, No Borders is uniquely positioned to use its expertise to improve margins and add business lines within target verticals. No Borders is headquartered in Arizona with remote work resources in the U.S., South America, Asia and Europe.

Different by Design

Deeply experienced at actionable data compilation, analysis and utilization, No Borders believes that data utilization in a Web 3 ecosystem of predictive analytics, blockchains, consensus algorithms, IoT and 5G are vital keys to the future of disrupting global business.

The company leverages its technological talent and visionary approach alongside best-in-class branding, messaging and product teams to simultaneously deploy multiple vertical product offerings at the same time.

With resources around the world, No Borders operates as a 100% remote work, lean operating organization with a founding ideological focus on “Lifestyle by Design.” No Borders’ teams are built by allowing people to work when they want and from where they want as long as deliverables and results are achieved. This structure allows for strategic talent acquisition without the need for relocation or commuting; lowered operating and fixed costs; as well as improved morale and substantially increased staff productivity.

NBDR Companies

• No Borders Dental Resources Inc. provides equipment and supplies to medical and dental professionals across the U.S. through the trade name, MediDent Supplies. MediDent has a strategic focus on expanding product portfolios and optimizing lifetime customer value while minimizing customer acquisition cost in the medical, dental and veterinary spaces.
• No Borders Naturals is a purveyor of health and wellness products for active consumers and their pets. No Borders Naturals aims to be an industry leader in alternative wellness product offerings and is currently expanding its digital offering with impactful product up-sell opportunities such as a series of “Buy Two-Get One” on products on its 1000mg CBD tincture, collagen and retinol beauty cream.
• No Borders Labs Inc. provides leading-edge tech tools to the No Borders family of companies along with building, testing and deploying technology solutions and products to the market while also offering consulting, architecture and software development services to external businesses looking to update their technology infrastructure for greater efficiency, security and transparency.
• No Borders Funding Inc. provides internal capital and strategic funding options for the family of No Borders companies while actively engaging and networking to find, acquire, structure and deploy unique financial products, solutions and systems with traditional, distributed ledger and blockchain technologies.
• No Borders Education Inc. provides internal staff training and strategic education tools for the No Borders family of companies while pursuing external revenue generating educational opportunities within the verticals for which No Borders deploys products, services or technologies.

Leadership

No Borders CEO Joseph Snyder is a serial entrepreneur whose experiences in real estate investment, financial services and digital strategy over the last 15 years provide a strong, grounded foundation for the structure and ideas outlined in the company’s strategic plan. He brings a unique set of long-term business experiences that provide No Borders with a clear “mile-high” view of the intricately linked systems and challenges associated with growing and scaling our vision.

COO Cynthia Tanabe, a licensed real estate agent/broker since 2004, has successfully built a highly respected investor and bank-focused real estate and property management firm in Arizona with tens of millions of dollars of properties owned and sold.

CTO Chris Brown has 14 years of experience in the IT industry ranging from full stack programming, hardware support, engineering and maintenance, to enterprise-level information system analysis, design, development and implementation. From his background in Air Force intelligence to earning dual B.S. degrees in computational mathematics and biochemistry from Arizona State University, Brown has been engrossed with technologies such as artificial intelligence, machine learning, and decentralized blockchain ledger systems and their connections with real world business applications.

Management is backed by an advisory board with a diverse range of expertise blockchain, brand development, specialty retail, branded consumer products, technology, marketing and other specialties pertinent to No Borders’ growth strategy.

For more information, visit the company’s website at www.NBDR.co

NOTE TO INVESTORS: The latest news and updates relating to NBDR are available in the company’s newsroom at http://ibn.fm/NBDR

• Plus Products’ focused on edible cannabis-infused products
• Company has dedicated food manufacturing facility in California
• PLUS product family includes newly launched CBD-infused gummies

Focusing on offering a consistent cannabis experience, Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF) produces edibles using extracts to ensure compliant, dosable and flavorful products supporting a healthy and active lifestyle. Headquartered in San Mateo, California, the company is fundamentally a branded, cannabis-infused products manufacturer, offering the #1 best-selling Cannabis products in California according to BDS Analytics. The company’s product team consists of chefs, chemists, food-manufacturing experts.

A hemp-and-cannabis food company, Plus Products’ emphasis is on thoughtfully and carefully building brand value. The company has already achieved its first strategic goal – to develop a winning brand in California – in PLUS gummies, and it looks to expand on that brand with the goal of creating the world’s strongest cannabis brand by taking its successful formula to new markets, new products, and new consumers (http://ibn.fm/RJmrM).

Plus Products sees potential for even more growth in branded products. New brands are creating new categories and subcategories, as well as different methods of consumption. The company is working to position itself to take advantage of these compelling opportunities.

Of note to investors is Plus Products’ commitment to owning the branded-product space. The company is building the leading branded-cannabis, product-manufacturing operation in California, home to the largest and most competitive cannabis market in the country. The company’s cannabis-infused edibles are sold by more than 360 licensed retailers across the state (http://ibn.fm/5eCVZ). With a leading brand in the largest cannabis market in the world as well as an impressive $34.1 million of capital on hand as of their Q2 2019 financials, PLUS is well-situated to execute on its vision.

For more information, visit the company’s website at www.PlusProducts.com

NOTE TO INVESTORS: The latest news and updates relating to PLPRF are available in the company’s newsroom at http://ibn.fm/PLPRF

• The company projects $19 million total revenue in 2019 and up to $104 million in 2020 as it scales operations to meet rising global demand
• Hemptown USA obtained and grew one million rare CBG seeds for the 2019 growing season, yielding 780,000 pounds of dried biomass, and producing 10.3-13.4 percent full-spectrum non-intoxicating cannabinoids

Hemptown USA is a privately-owned grower of full-spectrum, feminized hemp using premium-seed genetics. The company is the premier player on the cannabigerol (CBG) market which remains strong even as the price of cannabidiol (CBD) continues to experience price compression due to an explosion of hemp grown. One of the key phytocannabinoids present in feminized hemp, CBG has been attracting a lot of attention in the scientific community for its many anti-inflammatory and anti-bacterial properties. CBG is the precursor cannabinoid forming the basis for synthesis of all other cannabinoids, which is why it’s often referred to as the “stem cell” or “mother” of cannabinoids.

These unique features lend CBG great therapeutic promise. Studies show the compound can help regulate mood because it boosts anandamide, the native “pleasure” molecule, and acts as a GABA reuptake inhibitor (http://ibn.fm/6Aj5J). Research also suggests that CBG is a potent anti-inflammatory and anti-cancer agent (http://ibn.fm/ApDEA), as well as a good treatment option for anxiety and depression. In addition, research points to it having potential as an effective natural option for addressing medical problems like glaucoma, inflammatory bowel disease, neurological conditions, bladder disorders and bacterial conditions. CBG is also the key compound in a new FDA application for the treatment of skin conditions like psoriasis and eczema.

Research has however been limited due to the low concentration of CBG in plants. Feminized hemp plants must normally be harvested early in the growth process to capture the CBG before it changes its form to CBD and tetrahydrocannabinol (THC), but Hemptown USA plants have been designed to allow harvesting later at full maturity. They have also been designed to be far richer in CBG (10-14 percent). In 2020 and beyond, the company has exclusive rights to 20 percent of the latest and greatest novel cannabinoids being produced by their genetics partner.

Hemptown just completed in the fall of 2019 a 2.1-million-pound harvest of both CBG and CDB rich dried hemp biomass and will be scaling its down stream operations to meet global demand in the wake of the successful 2019 growing season. According to Hemptown data, the company is on track for 2019 revenue of $19 million and is projecting $104 million revenue for 2020 once down stream extraction/production is in full swing. In 2018, the company harvested 110,000 pounds of full-spectrum biomass with CBD content of around 14 percent from its Oregon hemp farms.

The company grew over 1,500 acres in Oregon, Colorado and Kentucky. The Oregon operation is focused exclusively on rare genetics and plans to expand cultivation to 800 acres for the 2020 growing season. Combined with its innovative harvesting measures, this uniquely positions Hemptown as the largest producer of CBG in North America and the world.

The scarcity of CBG and growing demand for the compound have led to an increase in popularity and market price for CBG-based products. In the U.S., the price for CBG distillate/isolate is now five to ten times higher than that of CBD oil and forecasts suggest that CBG will rival CBD’s popularity over the next few years.

With an average margin of 70-80 percent, Hemptown offers a diversified product line that includes top flower, distillate, biomass, isolate and water-soluble ready. Several consumer brands are presently in development with launch dates set for winter 2019. The benefits of Hemptown’s products for beverage, food, and cosmetic companies include purity, potency, cost effectiveness, and marketplace strength.

Headquartered in Portland, Oregon, Hemptown is a proven grower of broad-spectrum hemp biomass using premium seed genetics that contain less than 0.3 percent THC and exceptionally high CBD content of up to 20 percent. The company’s “soil to oil” methodology combines seasoned professionals working in hand-picked agricultural microclimates located in Oregon’s famed Emerald Triangle, as well as Kentucky and Colorado.

For more information, visit the company’s website at www.HemptownUSA.com

• Sigma Labs is revolutionizing the 3D metal printing process by reducing and in certain cases eliminating the need for costly and wasteful post-production inspections
• PrintRite3D software is first and only system that enables real-time, in-process detection of manufacturing irregularities for critical metal parts, provides real-time quality assurance using advanced visualizations to fix process and part irregularities.
• Sigma Labs’ IP portfolio covers advanced in process quality metric (IPQM) algorithmic techniques for the additive manufacturing laser powder bed quality control industry
• Company targets a growing multibillion-dollar global total addressable market
• Negotiating for lucrative machine OEM partnerships to advance “closed loop” technology roadmap
• Tier-1 OEM enterprises and end-users such as Airbus, Baker Hughes, Pratt & Whitney and others are currently evaluating PrintRite3D® for production lines.
• Sigma Labs technology team has developed an inclusive machine technology platform for all machine species that is capable for Single, Dual and Quad Laser machines on multiple OEM platforms.

Sigma Labs Inc. (NASDAQ: SGLB), a developer of latest-generation, non-destructive quality inspection systems for metal-based additive manufacturing and other advanced manufacturing technologies, is set to revolutionize 3D metal printing by eliminating the need for costly post-production inspections and ensuring quality control during the manufacturing process.

3D metal manufacturing or additive manufacturing utilizes lasers to sculpt parts by welding powdered metals into 3D objects. Quality of these parts can vary from machine to machine in a production line and even from part to part in a single production run. Conventional quality assurance methods rely on statistically based post-process inspection methods, which are not effective in improving and certifying 3D metal printer-made parts.

Sigma Labs’ flagship product, PrintRite3D(R), real-time-Computer-Aided Inspection (CAI), has the potential to solve the major problem that has kept large-scale 3D printing of metal parts from achieving cost efficient production runs. PrintRite3D’s patented and third party validated quality assurance software ensures certification and compliance with the hyper critical standards mandated in multiple precision dependent industries like aerospace, defense and biomedical. Sigma Labs’ PrintRite 3D reduces cost, time, waste and weight and allows manufacturers to economically scale up production.

Leading a Revolution in 3D Printing

Sigma Labs is about to radically alter the way critical components are created in the 3D metal printing industry. Heralded as the fourth industrial revolution in manufacturing, 3D printing must move beyond traditional quality control techniques to “in process” quality assurance to fully commercialize. To reduce quality control costs and enhance production speed, it’s necessary to inspect and certify 3D parts while they are being made, not after the fact.

Sigma Labs is already gaining traction with major industry players. In Q3 2019, the company announced a key partnership with Airbus (OTC: EADSY) (FRA: AIR) (http://ibn.fm/eKvRZ). Airbus is the European leader in the aeronautics space providing combat, tanker, mission, passenger and transport aircraft. It is also a leader in the global space industry. Under the agreement, Airbus will complete a Test and Evaluation Program of Sigma Labs’ new PrintRite3D® version 5.0 hardware and software followed by a validation phase on a powder bed fusion printer.

Sigma released the latest version of PrintRite3D(R), 5.0, in May 2019. It delivers a simple, fast, and user-friendly interface operable by both additive manufacturing machine operation technicians and sophisticated process engineers. This cross-functional effort now makes available capabilities that are of interest to a number of high-tech companies moving toward serial additive manufacturing. Version 5.0 enables Sigma and clients to identify unpredictably occurring, design- and metal-specific signatures of precursors of intermittent quality anomalies. So far, no other product has been capable of implementing these procedures at setup and then continuing in machine operation. Sigma Labs’ PrintRite3D(R) technology has no competition in providing actionable in-process data.

Sigma’s OEM licensing strategy and negotiations are crucial to securing deployment of PrintRite3D(R) on the growing marketplace direct from the factory. The product’s forte in these negotiations is integration of unique product functionality within an increasing portfolio of in-process patents. Sigma is fast overcoming the reluctance of OEM’s to adopt third-party quality assurance tools. Widely available tools like automatic braking and parking faced similar challenges early on and Sigma expects a similar outcome for adoption of its PrintRite3D(R) technology.

Significant Advantages to End Users

PrintRite3D(R) tracks the performance of each machine to provide early warnings of changes in machine performance using advanced melt pool quality metrics. X-rays and post process inspections are minimized, saving money and time and increasing production. Sigma is providing the solution the 3D printing industry has long sought, fueling the transition to a new manufacturing revolution.

PrintRite3D(R) has been independently validated as a key, reliable mechanism to ensure compliance and certification of 3D manufactured parts. The authoritative Defense Advanced Research Projects Agency (DARPA) (http://ibn.fm/rsbDS) found Sigma’s technology to “ensure process consistency and product quality in metal additive manufacturing.” DARPA also recognized its capability to monitor the condition of the manufacturing equipment and to certify quality and components.

3D additive metal part quality assurance requires high quality sensitive manufacturers to institute procedures to inspect every single part being made. The only way to attain high yields for cost efficiency and manufacturing quality is an in-process quality assurance approach. PrintRite3D determines whether parts meet quality specifications, examines each part as it’s being manufactured in real-time to ensure it isn’t deviating from specifications then signals the operator of a problem and the adjustments to be made. Machine operators are able to act on the information in real time rather than scraping the part after it has already been manufactured.

Sigma’s Capital Increase Strategy

In the spring of 2019, Sigma implemented a plan to ensure the company had sufficient capital to fund its commercial path this year. This seems to have been the right decision given market volatility. As of November 8, 2019, Sigma’s share volume was 254,273 with previous close at $0.56 per share and open of $0.55 per share. The company’s market cap is $9,254,435 (http://ibn.fm/yOO8m). Sigma has an optimistic outlook with a fortified balance sheet, a growing, multibillion total addressable market (TAM), a growing RTE program, and commercial orders with a clear line of sight to breakeven operations by early 2020. Sigma Labs is on the path to becoming a dominant industry force as it revolutionizes the 3D printing industry.

For more information, visit the company’s website at www.SigmaLabsInc.com

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB